[68Ga]Ga-PSMA-PET/CT imaging was performed on a Biograph mCT system (Siemens Healthineers, Erlangen, Germany) 1 week prior to each administration of [177Lu]Lu-PSMA to evaluate PSMA-positive tumor lesions, following local clinical acquisition protocols [30 (link)]. Standardized uptake values (SUV) were determined for salivary gland (SUVmean, spherical volumes of interest (VOIs) of 20 mm in diameter) and lesions (SUVmax). For dosimetry, all patients received SPECT/CT imaging at 1, 24, 48, 72, and 168 h after each therapy on either a Symbia T16 or Symbia Intevo Bold system (Siemens Healthineers, Erlangen, Germany). Both systems were cross-calibrated for 177Lu with the in-house dose calibrator, which undergoes regular quality control according to national guidelines [31 ]. Three-bed position SPECT/CT scans were acquired including the pelvis, abdomen, and head/neck region. The acquisition and reconstruction protocol was followed as described by Peters et al. [32 (link)] and was in accordance with MIRD pamphlet no. 26 [33 (link)]. These protocols take into account scatter, attenuation, and dead-time corrections.
Free full text: Click here